BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Gains Exclusive Development and Commercialization License from Max Planck for biobetter Anti-IL-17 Antibody
- BiondVax just signed an exclusive worldwide license agreement with the Max Planck Society to develop and commercialize innovative NanoAb therapeutics for the treatment of psoriasis and psoriatic arthritis
- Part of an ongoing broad-based collaboration targeting therapies addressing diseases such as Covid-19, asthma, and macular degeneration
- Per BiondVax’s CEO, Amir Reichman, this exclusive license presents an exciting opportunity to develop a unique treatment for psoriasis
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, just announced that it has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). The license agreement is part of a broad-based collaboration with the Max Planck Society and the University of Medical Center Göttingen (“UMG”). The NanoAbs will be targeted toward the treatment of several relevant indications, including, but not limited to, psoriasis and psoriatic arthritis (https://nnw.fm/6MYl6 ).
BiondVax’s collaboration with the Max Planck Institute for Multidisciplinary Sciences and UMG, both based in Germany, is producing a pipeline of innovative therapies addressing diseases underserved by current treatments, yet with large and growing markets. Previous development efforts have addressed diseases such as Covid-19, and BiondVax’s current venture with these two institutions is geared towards creating NanoAbs that target the large, underserved market of psoriasis, a chronic autoimmune disease that causes inflammation and scaling of the skin.
The condition affects over 7.5 million adults in the U.S. and an estimated 125 million people worldwide, yet currently available monoclonal antibodies (“mAbs”) therapies for the condition require an inconvenient systemic injection every four to eight weeks and come with adverse side effects, including exacerbation of Inflammatory Bowel Disease (“IBD”) (https://nnw.fm/uEJBv ). With BiondVax’s NanoAbs, it is possible to target not only IL-17A but also IL-17F and IL-17A/F complex, potentially generating superior efficacy in treating the condition.
Mr. Amir Reichman, BiondVax’s CEO, has lauded this exclusive license agreement, expressing his optimism that the company’s NanoAbs have the potential to provide a much-needed and vastly improved treatment option. He also termed it as a validation of the productivity of the collaboration among the three parties.
“The license of the IL-17 NanoAb from Max Planck is not only an exciting opportunity to develop a unique treatment for psoriasis and other autoimmune diseases but another validation of the productivity of our collaboration with Max Planck and UMG and portends additional significant developments to follow,” he noted.
According to Dr. Dieter Link, patent and licensing manager at Max Planck Innovation, this milestone marks a significant step toward the clinical application of the next VHH antibody candidates out of the larger group of NanoAbs contemplated by the collaborators.
“We are very pleased that the next antibody candidates out of a larger group pursued by the collaborators have successfully been generated, discovered, and characterized by the Max Planck Institute of Multidisciplinary Sciences,” he noted.
“BiondVax is well positioned to move this closer to and into clinical application,” he added.
BiondVax’s NanoAb platform has proven to have the potential to address a growing range of unmet medical needs. The company remains committed to developing innovative therapies that improve patients’ lives, with the recent exclusive Max Planck license key evidence of the potential for success in achieving BiondVax’s important goals.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- BiondVax just signed an exclusive worldwide license agreement with the Max Planck Society to develop and commercialize innovative NanoAb therapeutics for the treatment of psoriasis and psoriatic arthritis
- Part of an ongoing broad-based collaboration targeting therapies addressing diseases such as Covid-19, asthma, and macular degeneration
- Per BiondVax’s CEO, Amir Reichman, this exclusive license presents an exciting opportunity to develop a unique treatment for psoriasis
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, just announced that it has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). The license agreement is part of a broad-based collaboration with the Max Planck Society and the University of Medical Center Göttingen (“UMG”). The NanoAbs will be targeted toward the treatment of several relevant indications, including, but not limited to, psoriasis and psoriatic arthritis (https://nnw.fm/6MYl6 ).
BiondVax’s collaboration with the Max Planck Institute for Multidisciplinary Sciences and UMG, both based in Germany, is producing a pipeline of innovative therapies addressing diseases underserved by current treatments, yet with large and growing markets. Previous development efforts have addressed diseases such as Covid-19, and BiondVax’s current venture with these two institutions is geared towards creating NanoAbs that target the large, underserved market of psoriasis, a chronic autoimmune disease that causes inflammation and scaling of the skin.
The condition affects over 7.5 million adults in the U.S. and an estimated 125 million people worldwide, yet currently available monoclonal antibodies (“mAbs”) therapies for the condition require an inconvenient systemic injection every four to eight weeks and come with adverse side effects, including exacerbation of Inflammatory Bowel Disease (“IBD”) (https://nnw.fm/uEJBv ). With BiondVax’s NanoAbs, it is possible to target not only IL-17A but also IL-17F and IL-17A/F complex, potentially generating superior efficacy in treating the condition.
Mr. Amir Reichman, BiondVax’s CEO, has lauded this exclusive license agreement, expressing his optimism that the company’s NanoAbs have the potential to provide a much-needed and vastly improved treatment option. He also termed it as a validation of the productivity of the collaboration among the three parties.
“The license of the IL-17 NanoAb from Max Planck is not only an exciting opportunity to develop a unique treatment for psoriasis and other autoimmune diseases but another validation of the productivity of our collaboration with Max Planck and UMG and portends additional significant developments to follow,” he noted.
According to Dr. Dieter Link, patent and licensing manager at Max Planck Innovation, this milestone marks a significant step toward the clinical application of the next VHH antibody candidates out of the larger group of NanoAbs contemplated by the collaborators.
“We are very pleased that the next antibody candidates out of a larger group pursued by the collaborators have successfully been generated, discovered, and characterized by the Max Planck Institute of Multidisciplinary Sciences,” he noted.
“BiondVax is well positioned to move this closer to and into clinical application,” he added.
BiondVax’s NanoAb platform has proven to have the potential to address a growing range of unmet medical needs. The company remains committed to developing innovative therapies that improve patients’ lives, with the recent exclusive Max Planck license key evidence of the potential for success in achieving BiondVax’s important goals.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
